NOVO.B.DK

243.1

-4.44%↓

HLUNB.DK

39.32

+0.82%↑

AMBUB.DK

79.4

+0.44%↑

NOVO.B.DK

243.1

-4.44%↓

HLUNB.DK

39.32

+0.82%↑

AMBUB.DK

79.4

+0.44%↑

NOVO.B.DK

243.1

-4.44%↓

HLUNB.DK

39.32

+0.82%↑

AMBUB.DK

79.4

+0.44%↑

NOVO.B.DK

243.1

-4.44%↓

HLUNB.DK

39.32

+0.82%↑

AMBUB.DK

79.4

+0.44%↑

NOVO.B.DK

243.1

-4.44%↓

HLUNB.DK

39.32

+0.82%↑

AMBUB.DK

79.4

+0.44%↑

Search

Coloplast A-S (Class B)

Aperta

493.9 3.22

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

478.5

Massimo

494.3

Metriche Chiave

By Trading Economics

Entrata

522M

1.4B

Vendite

83M

7B

P/E

Media del settore

27.421

110.024

EPS

6.32

Rendimento da dividendi

4.84

Margine di Profitto

19.835

Dipendenti

16,983

EBITDA

309M

2.3B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+11.86% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.84%

2.26%

Utili prossimi

12 mag 2026

Prossima data del Dividendo

20 mag 2026

Prossima data del' Ex Dividendo

18 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-9.1B

110B

Apertura precedente

490.68

Chiusura precedente

493.9

Coloplast A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 feb 2026, 22:53 UTC

Acquisizioni, Fusioni, Takeovers

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Utili

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Utili

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Discorsi di Mercato
Utili

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Discorsi di Mercato
Utili

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Discorsi di Mercato

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Acquisizioni, Fusioni, Takeovers

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Acquisizioni, Fusioni, Takeovers

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Discorsi di Mercato

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Acquisizioni, Fusioni, Takeovers

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Acquisizioni, Fusioni, Takeovers

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Utili

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Utili

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Utili

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Utili

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Utili

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Utili

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Discorsi di Mercato

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Utili

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Utili

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Utili

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Utili

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Utili

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Utili

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Utili

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Utili

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Utili

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Confronto tra pari

Modifica del prezzo

Coloplast A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

11.86% in crescita

Previsioni per 12 mesi

Media 901.38 DKK  11.86%

Alto 1,056 DKK

Basso 720 DKK

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coloplast A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

2

Acquista

4

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat